Dr. Abraham Lin is no stranger to interdisciplinary research, having a background in Nuclear Engineering (B.S.E) from the University of Michigan – Ann Arbor, Biomedical Engineering (PhD) from Drexel University, and now working as a joint postdoctoral researcher in the Center for Oncological Research (CORE) and the Plasma Lab for Sustainability and Medicine – Antwerp (PLASMANT) at the University of Antwerp, Belgium. Previously, he worked for NASA, where he studied using plasma, an ionized gas, for space propulsion before transitioning to study how the same technology can be used for cancer immunotherapy. Now, he is part of a team (Orbits) that is investigating how computer vision and artificial intelligence can be applied for advanced image analysis to unlock the full potential of next-generation, ‘patient-in-the-lab’ cancer models, known as patient-derived organoids. He hopes that by integrating these different technologies together, he can help researchers predict how cancer patients will respond to different therapies in the clinic. This could ultimately help researchers develop more effective drugs and help clinicians move towards more personalized cancer medicine.